Post-earnings recap
Reported
Wed, May 20, 2026
EPS actual
$0.28
EPS est.
$-0.38
EPS surprise
+174.67%
1-day move
+14.89%
Roivant Sciences reported a strong earnings surprise with an EPS of $0.28, significantly beating expectations. However, revenue figures were not disclosed, leaving some uncertainty. The stock reacted positively, rising nearly 15%, likely driven by the unexpected profitability in EPS.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.28 | $-0.35 | +174.67% |
| Revenue | — | $4M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative therapies to improve patient outcomes. Operating in the health care sector, Roivant is known for its unique approach to drug development and commercialization, which could play a significant role in addressing unmet medical needs.
Last quarter
In the last quarter, Roivant reported an EPS of $-0.38, slightly beating expectations of $-0.39. The stock reacted positively, rising by over 22% the following day.
Management promises and guidance
EPS beat streak
4Q
EPS beat rate
63%
Avg EPS surprise
+49.21%
Avg 1-day reaction
+5.31%
Analysts expect Roivant to report a loss this quarter, with a consensus EPS of $-0.35 and revenue of $4M. Investors will be keen to see if the company can meet or exceed these expectations.
Bull case
If Roivant can report better-than-expected earnings and revenue, it may signal strong demand for its therapies and boost investor confidence.
Bear case
Conversely, if the company misses its targets, it could raise concerns about its financial stability and future growth prospects.
Key metrics to watch
Earnings Per Share (EPS)
$-0.35EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
$4MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Roivant's EPS meet or exceed the consensus estimate of $-0.35?
A beat on EPS could indicate improved operational efficiency and stronger market demand.
Q2
What revenue figures will Roivant report, and how do they compare to the $4M consensus?
Revenue performance is crucial for assessing the company's growth trajectory and market acceptance of its products.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±8.9%
Why consensus could be wrong
The consensus may underestimate Roivant's potential for revenue growth due to recent advancements in its clinical trials.
Supporting evidence
The company has a history of surprising on EPS, with a 63% beat rate over the last eight quarters.
Recent insider selling could indicate confidence in the company's future performance despite current losses.
Key risk
If revenue comes in significantly above $4M, it could challenge the current bearish outlook.
Pre-commit to what would confirm each case.
The market is debating Roivant's ability to generate revenue and control losses, which are critical for its future growth.
Bull confirmed if
Reporting an EPS of $-0.26 or better, along with revenue exceeding $5M, would confirm the bull case.
Bear confirmed if
An EPS worse than $-0.49 and revenue below $3M would support the bear case.
What the market is pricing for the move.
Implied Move
±7.00%
Historical Avg
±6.6%
The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility.
Options are pricing ±7.0% while ROIV has averaged ±6.6% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.5%
30d HV
28.0%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$8.0M
217,750 sh
2 insiders
Net
$8.0M
Net selling
Most Active Insiders· 3 open-market trades
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Roivant beats expectations, history suggests a potential stock increase of around 5.5%, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.
Miss
A miss on earnings could lead to a decline, with historical data indicating an average drop of around 0.7%.
The lines on the call that would change the story.
$640,861.00
Net selling
$7.3M
Net selling
Recent Transactions
Sep 30, 2026 · @ $36.62
200,000 sh
$7.3M
Oct 1, 2026 · @ $36.08
16,850 sh
$607,948.00
Oct 1, 2026 · @ $36.57
900 sh
$32,913.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.